A detailed history of Jpmorgan Chase & CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,012,476 shares of RGNX stock, worth $26.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,012,476
Previous 3,722,553 19.08%
Holding current value
$26.4 Million
Previous $78.4 Million 55.06%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$11.51 - $21.53 $8.17 Million - $15.3 Million
-710,077 Reduced 19.08%
3,012,476 $35.2 Million
Q1 2024

May 10, 2024

SELL
$12.17 - $24.61 $2.64 Million - $5.34 Million
-216,996 Reduced 5.51%
3,722,553 $78.4 Million
Q4 2023

Feb 12, 2024

BUY
$12.89 - $20.82 $3.53 Million - $5.71 Million
274,185 Added 7.48%
3,939,549 $70.7 Million
Q3 2023

Nov 14, 2023

SELL
$16.46 - $19.99 $596,098 - $723,937
-36,215 Reduced 0.98%
3,665,364 $60.3 Million
Q2 2023

Aug 11, 2023

SELL
$17.23 - $21.71 $5.24 Million - $6.6 Million
-304,044 Reduced 7.59%
3,701,579 $74 Million
Q1 2023

May 18, 2023

BUY
$18.08 - $24.55 $889,789 - $1.21 Million
49,214 Added 1.24%
4,005,623 $75.7 Million
Q1 2023

May 11, 2023

BUY
$18.08 - $24.55 $2.93 Million - $3.98 Million
161,932 Added 4.27%
3,956,409 $74.8 Million
Q4 2022

Feb 13, 2023

SELL
$20.4 - $24.73 $5.31 Million - $6.43 Million
-260,178 Reduced 6.42%
3,794,477 $86.1 Million
Q3 2022

Nov 14, 2022

SELL
$22.29 - $35.04 $4.24 Million - $6.67 Million
-190,241 Reduced 4.48%
4,054,655 $107 Million
Q2 2022

Aug 11, 2022

SELL
$19.35 - $35.04 $9.28 Million - $16.8 Million
-479,797 Reduced 10.16%
4,244,896 $105 Million
Q1 2022

May 11, 2022

SELL
$24.62 - $34.31 $6.9 Million - $9.61 Million
-280,080 Reduced 5.6%
4,724,693 $157 Million
Q4 2021

Feb 10, 2022

BUY
$30.19 - $40.28 $26.1 Million - $34.8 Million
864,447 Added 20.88%
5,004,773 $164 Million
Q3 2021

Nov 12, 2021

BUY
$29.09 - $45.68 $120 Million - $189 Million
4,140,326 New
4,140,326 $174 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $379M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.